Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
2017 · The Lancet Oncology · 247 citations
https://doi.org/10.1016/s1470-2045(16)30671-4